Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 - PubMed (original) (raw)
. 2005 Oct;16(10):1569-83.
doi: 10.1093/annonc/mdi326. Epub 2005 Sep 7.
Affiliations
- PMID: 16148022
- DOI: 10.1093/annonc/mdi326
Free article
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
A Goldhirsch et al. Ann Oncol. 2005 Oct.
Free article
Abstract
The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER 2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.
Comment in
- St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy.
Buzdar AU. Buzdar AU. Ann Oncol. 2006 May;17(5):878-9. doi: 10.1093/annonc/mdj093. Ann Oncol. 2006. PMID: 16638951 No abstract available.
Similar articles
- Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer.
Horii R, Akiyama F, Ito Y, Iwase T. Horii R, et al. Br J Cancer. 2007 Sep 3;97(5):654-8. doi: 10.1038/sj.bjc.6603916. Epub 2007 Aug 28. Br J Cancer. 2007. PMID: 17726451 Free PMC article. - First--select the target: better choice of adjuvant treatments for breast cancer patients.
Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ; St Gallen Expert Panel Members. Goldhirsch A, et al. Ann Oncol. 2006 Dec;17(12):1772-6. doi: 10.1093/annonc/mdl398. Epub 2006 Oct 27. Ann Oncol. 2006. PMID: 17071934 - Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Goldhirsch A, et al. Ann Oncol. 2007 Jul;18(7):1133-44. doi: 10.1093/annonc/mdm271. Ann Oncol. 2007. PMID: 17675394 Review. - Adjuvant therapy for breast cancer.
[No authors listed] [No authors listed] NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. NIH Consens Statement. 2000. PMID: 11512506 Review.
Cited by
- Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer.
Mizoguchi K, Kawaji H, Kai M, Morisaki T, Hayashi S, Takao Y, Yamada M, Shimazaki A, Osako T, Arima N, Okido M, Oda Y, Nakamura M, Kubo M. Mizoguchi K, et al. Cancers (Basel). 2023 Sep 7;15(18):4456. doi: 10.3390/cancers15184456. Cancers (Basel). 2023. PMID: 37760424 Free PMC article. - Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare.
Müller V, Fasching PA, Nabieva N, Fehm TN, Thill M, Schmidt M, Kühn T, Banys-Paluchowski M, Belleville E, Juhasz-Böss I, Untch M, Kolberg HC, Harbeck N, Aktas B, Stickeler E, Kreuzeder J, Hartkopf AD, Janni W, Ditsch N. Müller V, et al. Geburtshilfe Frauenheilkd. 2023 May 23;83(6):673-685. doi: 10.1055/a-2073-1887. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37614683 Free PMC article. - Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer.
Jannusch K, Bittner AK, Bruckmann NM, Morawitz J, Stieglitz C, Dietzel F, Quick HH, Baba HA, Herrmann K, Umutlu L, Antoch G, Kirchner J, Kasimir-Bauer S, Hoffmann O. Jannusch K, et al. Cancers (Basel). 2023 Mar 8;15(6):1651. doi: 10.3390/cancers15061651. Cancers (Basel). 2023. PMID: 36980537 Free PMC article. - Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry.
Kangleon-Tan HL, Sim J, You JY, Lee ES, Lee H, Yang SM, Seong MK, Park EH, Nam SJ, Park MH, Lee S, Park WC, Kangleon RG Jr, Dy CB, Bae SY, Jung SP; Korean Breast Cancer Society. Kangleon-Tan HL, et al. Ann Surg Treat Res. 2022 Dec;103(6):313-322. doi: 10.4174/astr.2022.103.6.313. Epub 2022 Dec 8. Ann Surg Treat Res. 2022. PMID: 36601341 Free PMC article. - Breast cancer radiation therapy: A bibliometric analysis of the scientific literature.
Franco P, De Felice F, Jagsi R, Nader Marta G, Kaidar-Person O, Gabrys D, Kim K, Ramiah D, Meattini I, Poortmans P. Franco P, et al. Clin Transl Radiat Oncol. 2022 Dec 5;39:100556. doi: 10.1016/j.ctro.2022.11.015. eCollection 2023 Mar. Clin Transl Radiat Oncol. 2022. PMID: 36545362 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous